Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosalvudine tidoxil
- Development stage
- Discontinued
- Lead developer
- Heidelberg Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fosalvudine tidoxil is an orally bioavailable small molecule nucleoside reverse transcriptase inhibitor (NRTI) prodrug. It was developed by Heidelberg Pharma (formerly Wilex AG) for the treatment of HIV-1 infection. The drug is a lipid conjugate of alovudine (3-deoxy-3-fluorothymidine; FLT), designed to improve the safety profile and reduce the bone marrow and liver toxicity associated with the parent compound. Upon administration, it is metabolized to alovudine triphosphate, which inhibits the viral reverse transcriptase enzyme, thereby preventing HIV replication. Development reached Phase II clinical trials in Germany but was subsequently discontinued.
- Other names
- alovudine tidoxil3-deoxy-3-fluorothymidine-5-(hexadecyloxypropyl) hydrogen phosphate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHIV-2 reverse transcriptasePOLG (Mitochondrial DNA polymerase gamma)Human nuclear DNA polymerase
Beyond the preview
Go deeper on fosalvudine tidoxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosalvudine tidoxil.